Rekombinanter IL17A (Secukinumab Biosimilar) Antikörper
Dieser Humanized Monoklonal Antikörper erkennt spezifisch IL17A (Secukinumab Biosimilar) in FACS und in vivo. Er zeigt eine Reaktivität gegenüber Human.
Produktnummer ABIN7795097
Kurzübersicht für Rekombinanter IL17A (Secukinumab Biosimilar) Antikörper (ABIN7795097)
Target
IL17A (Secukinumab Biosimilar)
Antikörpertyp
Recombinant Antibody
Reaktivität
Human
Wirt
Humanized
Klonalität
Monoklonal
Konjugat
Dieser IL17A (Secukinumab Biosimilar) Antikörper ist unkonjugiert
Applikation
Flow Cytometry (FACS), In vivo Studies (in vivo)
Güteklasse
Research Grade
-
-
Expressionssystem
- Mammalian cells
-
Verwendungszweck
- Secukinumab Biosimilar, Human IL17A Monoclonal Antibody
-
Produktmerkmale
- What is secukinumab biosimilar research grade? Research grade secukinumab biosimilar uses the same protein sequences as the therapeutic antibody secukinumab. Secukinumab, the humanized anti-IL17A monoclonal antibody, inhibits interleukin 17A, which is a member of the cytokine family, and produced mainly by inflammatory T helper 17 cells. IL17A is upregulated in serum of people with psoriasis and in the synovial fluid of people with psoriatic arthritis, and promotes inflammation when it binds to the interleukin-17 receptor which is expressed in various types of cells, including keratinocytes in skin.
-
Aufreinigung
- Protein A or G affinity column
-
Reinheit
- >95 % by reducing SDS-PAGE
-
Endotoxin-Niveau
- < 1 EU per 1 mg of the protein by the LAL method
-
Immunogen
- Human IL17A
-
-
-
-
Applikationshinweise
- Optimal working dilution should be determined by the investigator.
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Konzentration
- > 3 mg/mL
-
Lagerung
- 4 °C,-20 °C
-
Informationen zur Lagerung
- Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.
-
-
- IL17A (Secukinumab Biosimilar)
-
Andere Bezeichnung
- Secukinumab Biosimilar
-
Substanzklasse
- Biosimilar
Target
-
Sie sind hier:
